Recce Pharmaceuticals Shares Spike 24% Higher on News of US Interest

Last week, Recce Pharmaceuticals Ltd [ASX:RCE] had a major win.

This tiny biocap stock divulged that it was going to be working with the CSIRO on tests. Analysing their anti-infectives in the fight against COVID-19.

I covered it in detail, right here.

Now though, one week on, Recce has even more good news to share. Because it isn’t just Australian scientists that are interested in their work anymore, US researchers are also keen…

A revelation that has seen the company’s stock spike 24% higher in trading today.

A global pandemic, calls for a global solution

Path BioAnalytics is the company behind the American interest. A North Carolina-based, private biotech company.

The plan, just like with the CSIRO, is to evaluate the effectiveness of Recce’s anti-infectives. Conducting a study within several ‘state-of-the-art Biosafety Level 3 containment laboratories.’

If all goes to plan, we should get some early data by September. A testament to the quick turnaround time, and urgency to in addressing this pandemic.

As Recce’s non-executive chairman, John Prendergast, notes:

The current pandemic underscores the need for more effective treatment approaches to prevent infectious diseases.

Over the past few months Recce has received a number of expressions of interest from several universities and research organisations to collaborate on the development of potential new therapies to address the unmet needs of patients with COVID-19.

We’re excited to be working with experts at Path BioAnalyutics to investigate the potential effectiveness of Recce’s compounds in treatment of SARS-CoV-2 infection using their advanced respiratory organoid model system.

For Recce it is a huge endorsement of their potential.

One that may just help us find a way to deal with this daunting virus. Or perhaps, if we’re lucky, even provide a cure.

And for shareholders, it may even provide more incredible returns.

Trial and error

Just as I said last time though, this will likely be a lengthy process.

Even if the preliminary data comes back positive, it will take time to develop a treatment. Let alone get it to the point people can actually get their hands on it.

In time though, hopefully it will lead to a good outcome.

Which, like I said, could lead to some great gains for investors. It all depends on whether you’re willing to take a speculative punt or not.

However, Recce isn’t the only innovative stock in the market right now. There are plenty of other stocks with just as much potential, and stronger fundamentals. Companies which could provide some incredible returns in the coming months.

Read all about these ‘high-value small-caps’ in our complete report, right here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning


Ryan Clarkson-Ledward is one of Money Morning’s analysts.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan’s primary focus is assisting Sam Volkering with background research and insight for readers by dissecting the latest events affecting the world. Working closely with Sam, they explore the latest in small-cap and technology stocks as well as cryptocurrency opportunities.

You can find Ryan’s contributing research, developments, and supporting information across several e-letters, including:


Leave a Reply

Your email address will not be published. Required fields are marked *

Money Morning Australia